EXCLUSIVE: FENIX Interview with CGM Newcomer Allez Health (Part 1)
To kick off the ADA 2024 conference, FENIX sat down with Leif Bowman, the co-founder of Allez Health, for an in-depth interview on the company’s goal to disrupt the CGM market. Recall, in May 2024, Allez announced it secured $60M in a Series A+ financing round led by Osang Healthcare Co. Ltd and with participation from existing investors (previous FENIX insight). For context, Allez (formerly called Zense-Life; view website) is an emerging biosensor venture founded by veterans in the CGM space. Below, FENIX provides Part 1 of our exclusive interview which includes insight into Allez’s business philosophy as well as an early look into the features of its CGM.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.